by Jordana Choucair | Nov 17, 2021 | Life Sciences
The Biden administration plans to pay more than $5 billion for a stockpile of Pfizer’s new COVID-19 pill, enough for about 10 million courses of treatment to be delivered in the next 10 months. Senior federal health officials are counting on the five-day antiviral...
by Jordana Choucair | Nov 17, 2021 | Life Sciences
The FDA’s committee of outside experts is not planning to meet to discuss the data on Pfizer’s request for the agency to authorize COVID-19 boosters for all adults. The panel twice voted to reject boosters for the young and healthy who don’t face high exposure risks....
by Jordana Choucair | Nov 16, 2021 | Life Sciences
Pfizer has agreed to a licensing deal with the U.N.’s Medicines Patent Pool for its COVID-19 pill. Under the agreement, Pfizer will manufacture and supply its effective antiviral pill in 95 countries, including all low-income and lower-middle-income nations. The...
by Jordana Choucair | Nov 16, 2021 | Life Sciences
The Biden administration is withdrawing a Trump-era policy that limited the FDA’s review process of certain lab tests, including some COVID-19 tests. Under the policy, the agency did not require premarket reviews of laboratory-developed tests, even in situations...
by Jordana Choucair | Nov 15, 2021 | Life Sciences
California, Colorado, and New Mexico are moving ahead of federal guidance by expanding eligibility for COVID-19 booster shots to all adults. The policies are an attempt to mitigate a feared surge around the end-of-year holidays. Colorado and New Mexico have among the...
by Jordana Choucair | Nov 12, 2021 | Life Sciences
Health care conglomerate Johnson & Johnson announced it is planning to break up into two companies, separating its consumer health business into a new publicly traded company. “The new Johnson & Johnson and the New Consumer Health Company would each be...
Recent Comments